Company Overview of Epizyme, Inc.
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. The company’s proprietary product platform creates small molecule inhibitors of enzymes known as histone methyltransferases (HMTs). Its lead product candidate includes tazemetostat, an inhibitor of the EZH2 HMT, which is in Phase II clinical study in adults with relapsed or refractory non-Hodgkin lymphoma; and in phase II study in adults and phase I study in children with certain genetically-defined solid tumors, as well as for the treatment of mesothelioma. The company is also developing additional programs, including a Phase I clinical trial of pinometostat, an inhibi...
400 Technology Square
Cambridge, MA 02139
Founded in 2007
Key Executives for Epizyme, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $293.5K
Chief Financial Officer, Executive Vice President of Finance & Administration and Treasurer
Total Annual Compensation: $500.8K
Chief Scientific Officer and President of Research
Total Annual Compensation: $595.0K
Chief Medical Officer and Executive Vice President
Total Annual Compensation: $163.7K
Compensation as of Fiscal Year 2015.
Epizyme, Inc. Key Developments
Epizyme Announces Executive Appoints
Apr 25 16
Epizyme, Inc. announced that it has expanded its executive leadership team with the addition of Susan Graf, who joins the company as Chief Business Officer. Ms. Graf will report directly to Epizyme’s President and Chief Executive Officer, Robert Bazemore. Additionally, over the last quarter, Jeannie Chu joined the company as Vice President of Program and Portfolio Management and Michael Boretti joined as Vice President of Business Development. As Epizyme’s first Chief Business Officer, Ms. Graf will oversee and direct the implementation of Epizyme’s new corporate strategy and lead corporate and business development and alliance management. Ms. Graf was most recently Vice President, Corporate Development and Strategy for NPS Pharma before it was acquired by Shire in 2015. Jeannie joined Epizyme in February 2016 as Vice President of Program and Portfolio Management. In this role, Jeannie has begun to create structured, cross-functional project teams to oversee the development and commercialization of tazemetostat, as well as development of Epizyme’s portfolio of epigenetic products. Prior to Epizyme, Jeannie held roles of increasing responsibility at Biogen, most recently as Senior Director of Program Leadership and Management. Michael joined Epizyme as Vice President of Business Development in March 2016. In this role, Michael has already begun to lead new partnering opportunities, as well as ongoing alliances. Prior to Epizyme, Michael worked in roles of increasing responsibility at AVEO Oncology from 2008 to March 2016, most recently serving as Vice President, Corporate Development and Alliance Management.
Epizyme, Inc. Presents Data from Tazemetostat Clinical Pharmacology Studies at American Association for Cancer
Apr 18 16
Epizyme, Inc. presented data from clinical studies that investigated the effect of food intake on the pharmacokinetics of tazemetostat, the company’s lead investigational medicine, and the effect of tazemetostat on drugs that are metabolized by the enzyme CYP3A4/5. Epizyme reported that tazemetostat can be dosed with or without food and that the product candidate is a weak inducer of CYP3A-mediated metabolism, suggesting any potential interactions with other treatments metabolized through this pathway will be mild. The data were presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting. Tazemetostat is a first-in-class oral EZH2 inhibitor in phase 2 development for patients with non-Hodgkin lymphoma (NHL) and patients with certain genetically defined solid tumors. Epizyme presented results from a 13-patient study on the effect of food on the pharmacokinetics of tazemetostat in subjects with advanced solid tumors or B-cell lymphomas. Pharmacokinetic studies serve to provide information about the absorption and metabolism of medicinal compounds. The area under the plasma concentration-time curve (AUC) and maximum plasma concentration (Cmax) are pharmacokinetic parameters of the overall exposure to a drug following administration.
Epizyme Seeks Acqusition
Apr 15 16
Epizyme, Inc. (NasdaqGS:EPZM) filed a shelf registration in the amount of $250 million and intend to use the net proceeds from the sale of any securities for research and development of our product pipeline, acquisition of companies or businesses, repayment and refinancing of debt, working capital and capital expenditures.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|